Experimental studies and some clinical investigations have indicated that Amipaque (metrizamide) is less cardiotoxic than other contrast media in common use for angiocardiography. It, therefore, seemed motivated to find out whether these findings are valid in the high-risk group of neonates and small infants subjected to angiocardiography.